How This Evidence Evolved
CAR-T Cell Therapy
From concept to clinical reality
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
ZUMA-1 phase 2: ORR 82%; CR 54% (101 infused).
Remission (CR/CRi) within 3 months: 81% (75 infused).
Objective response in efficacy-evaluable patients: 186/256 (73%, 95% CI 66.8–78.0); complete response 136/256 (53%, 46.8–59.4).
Follow-up studies, subgroup analyses, and real-world validation
Median follow-up 13.3 mo: response 73%; CR or better 33% (128 treated)
Median follow-up 27.7 months: ORR 97.9%; sCR 82.5%.
Median EFS after median follow-up 24.9 months: axi-cel 8.3 vs standard care 2.0 months (HR 0.40, 95% CI 0.31 to 0.51; P<0.001).
Integration into clinical practice guidelines and recommendations
Use ASTCT consensus definitions and grading for CRS and neurotoxicity.
Current standard of care and ongoing research directions
Landmark Trials in This Story
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
ZUMA-1 phase 2: ORR 82%; CR 54% (101 infused).
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Remission (CR/CRi) within 3 months: 81% (75 infused).
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Objective response in efficacy-evaluable patients: 186/256 (73%, 95% CI 66.8–78.0); complete response 136/256 (53%, 46.8–59.4).
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Median follow-up 13.3 mo: response 73%; CR or better 33% (128 treated)
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Median follow-up 27.7 months: ORR 97.9%; sCR 82.5%.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Median EFS after median follow-up 24.9 months: axi-cel 8.3 vs standard care 2.0 months (HR 0.40, 95% CI 0.31 to 0.51; P<0.001).
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.